Merck said its board authorized an additional $10 billion share repurchase authorization, which has no time limit for completion. The maker of medicines and vaccines has a market cap of $247.75 ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 62 tables and 55 figures, this 142-page report ?Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, ...

Request To Download Free Sample of This Strategic Report@ Highlighted with 59 tables and 54 figures, this 141-page report ?Asia Pacific Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, ...

The CDC revised its pneumococcal pneumonia shot recommendation, saying there is a substantial increase in the risk for ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

We recently compiled a list of the 10 Best Russell 2000 Stocks to Invest in According to Analysts. In this article, we are ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...